以糖蛋白类肿瘤标志物为靶向的嵌合抗原受体修饰T细胞研究.PDFVIP

临床与病理杂志 2015, 35(1) 132 J Clin Path ol R e s doi: 10.3978/j.issn.2095-6959.2015.01.030 View this article at: /10.3978/j.issn.2095-6959.2015.01.030 以糖蛋白类肿瘤标志物为靶向的嵌合抗原受体 修饰T细胞研究进展 莫然，王东进 综述 (南京大学医学院附属鼓楼医院心胸外科，南京 210008) [摘　要] 嵌合抗原受体 (chimeric antigen receptor ，CAR)修饰T 细胞是目前肿瘤治疗中新的靶向疗法，通过 单链抗体 (single chain fragment variable ，scFv)-共刺激分子-T细胞信号转导区构成的嵌合模式修饰T 细胞，赋予T 细胞非MHC 依赖性靶向杀伤肿瘤细胞的能力，在动物模型及临床试验中取得了良好 的效果。糖蛋白类肿瘤标志物由于其良好的靶向性成为了CAR修饰T 细胞新的靶点，针对糖蛋白类 肿瘤标志物的靶向研究显示出良好的临床前景，但是也要考虑到脱靶效应，转染方式等问题对该 治疗在临床运用的限制。相信随着研究的逐渐深入，基于CAR修饰T 细胞的糖蛋白类肿瘤标志物靶 向治疗会取得更大的突破。 [关键词] 嵌合抗原受体；糖蛋白类肿瘤标志物；基因治疗；靶向治疗 Research progress in chimeric antigen receptor modified T cells targeted glycoprotein tumor marker MO Ran, WANG Dongjin (Department of Cardiothoracic Surgery, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing 210008, China) Abstract Chimeric antigen receptor (CAR) modified T cells is an emerging targeted therapy, CAR is consisted of single chain fragment variable (scFv), costimulatory molecules and T cells signal transduction domain, which could make T cells non-MHC-restricted targeting kill tumor cells. Experiments of CAR modified T cells in both animal models and clinical practice have got satisfied results. Glycoprotein tumor markers are promising targets of CAR modified T cells because of their favorable targeting. Targeted therapy researches aim at glycoprotein tumor marker rev